About Invest Ontario
Invest Ontario is the dedicated agency for investment attraction in the province. We serve as global businesses’ partner and one-window access to Ontario, providing expertise and tailored services throughout their investment journey. With a focus on the advanced manufacturing, life sciences and technology sectors, we are committed to securing strategic investments that create jobs, generate returns to the province and drive Ontario’s long-term economic growth and global competitiveness.
About SK Life Science, Inc. and SK Biopharmaceuticals Co., Ltd.
SK Life Science, Inc., with headquarters in Paramus, New Jersey, is a U.S. subsidiary of SK Biopharmaceuticals Co., Ltd., a pioneering South Korean company in drug development and commercialization. Together, they are advancing innovative treatments for central nervous system (CNS) disorders and oncology, with eight compounds currently in development. Utilizing target-based drug discovery, high-throughput organic screening/high content screening, computer-aided drug design, and combinatorial chemistry, the companies drive R&D efforts in biology/discovery, medicinal chemistry, pharmacology, and clinical development. For more information, visit www.SKLifeScienceInc.com.
SK Biopharmaceuticals Co., Ltd. is part of SK Group, South Korea’s second-largest conglomerate. SK Group is a collection of global industry-leading companies driving innovations in energy, advanced materials, biopharmaceuticals and digital business. Based in Seoul, SK invests in building sustainable businesses around the world with a shared commitment to reducing global greenhouse gas emissions. SK companies combined have $151 billion in global annual revenue and employ more than 100,000 people worldwide. SK Group is one of TIME’s 100 Most Influential Companies of 2023. SK Inc., the parent company of SK Biopharmaceuticals, continues to enhance its portfolio value by executing long-term investments with a number of competitive subsidiaries in various business areas, including pharmaceuticals and life science, energy and chemicals, information and telecommunication, and semiconductors. In addition, SK Inc. is focused on reinforcing its growth foundations through profitable and practical management based on financial stability, while raising its enterprise value by investing in new future growth businesses. For more information about SK Inc., visit For more information about SK Biopharmaceuticals, visit www.skbp.com/eng.
About Eurofarma
Established in 1972, Eurofarma operates in the health industry, producing and selling products and services to improve people’s quality of life. With a focus on generating shared value, it covers the main pharmaceutical segments, such as prescription, OTC and personal care, generics, hospital, oncology, and animal health, as well as providing production services to third parties. With a broad coverage of therapeutic classes, the portfolio comprises more than 2,000 products and 3,700 SKUs (presentations), serving the main medical specialties.
Leader in medical products prescriptions in Latin America, Eurofarma is present in 22 countries with the largest sales force in the region, with coverage of 100% of Latin America countries and operations in the USA and Africa. It has more than 12,600 employees and 11 factories, with total production around 700 million units in the last year. The company invested more than R$ 700 million in innovation and achieved total net revenue of R$ 11.1 billion. Over the last 15 years, Eurofarma has recorded average annual growth of 17%.
About Mentis Care
Mentis Care is an AI-driven digital health company transforming neurological care through the first predictive AI platform for brain health. The platform is designed to detect and forecast seizures and other neurological events in real time. By combining advanced machine learning with clinical expertise, Mentis Care aims to give patients and families greater safety, confidence, and peace of mind — while setting a new global standard in brain health and digital neuromonitoring.
link